5 questions answered from cited research · Plain language
The study identified three biomarkers (ARHGEF3, S100A8, RHOU) that show high diagnostic accuracy for ulcerative colitis, but their ability to diagnose Crohn's disease specifically was not established.
Read the full answer →Yes, the FDA has approved newer drugs for Crohn's disease, including Stelara (ustekinumab) and Hadlima (adalimumab), and selective IL-23 inhibitors are emerging as promising options.
Read the full answer →Yes, enteral nutrition therapy can help Crohn's disease patients achieve remission, especially exclusive enteral nutrition (EEN) in children, with evidence also supporting partial enteral nutrition (PEN) combined with exclusion diets in adults.
Read the full answer →People with Crohn's disease typically have lower gut bacteria diversity and an altered microbial community compared to healthy individuals.
Read the full answer →People with Crohn's disease have significantly lower oral microbial diversity compared to healthy individuals, with specific bacterial shifts and reduced butyrate metabolism.
Read the full answer →